Therefore, we decided to exploit the Ndufs4−/− mouse model (Kruse et al, 2008) to further characterize and validate the efficacy of miR‐181a/b inactivation in mammalian models of MDs. This evidence concerns the gene NDUFS4 and myelodysplastic syndrome.